Author of

• 25934

  +

  P1.14 - Thymoma/Other Thoracic Malignancies (Not CME Accredited Session) (ID 946)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall

  • 26641

    +

    P1.14-04 - Stereotactic Body Radiation Therapy for Pleural Recurrences of Thymoma (ID 14075)

    16:45 - 18:00  |  Author(s): Gustin Pierre
    • Abstract
    • Slides

    Background
    

    Pleural recurrences are not uncommon as a result of thymoma evolution; yet there is no therapeutic standard for their treatment. The purpose of this study was to evaluate the efficacy and tolerability of stereotactic body radiation therapy (SBRT) for the treatment of pleural metastasis.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    A single institution retrospective study of the patients treated with SBRT using Novalis and VMAT, with doses of 30Gy in 5 fractions or 40Gy in 10 fractions. Treatment responses were evaluated using TDM and/or TEP TDM

    4c3880bb027f159e801041b1021e88e8 Result
    

    In the period 2014-2017, 10 patients (6 women, 4 men) with a median age of 51 and a total of 21 pleural recurrences were treated with SBRT. Initial Masaoka-Koga stages were: 1 I, 3 IIb, 3 III, 2 IVa and 1 unknown. Nine of them had previously been treated for other pleural recurrences (7 had surgery, 2 conformational RT and 3 chemotherapy).

    All patients were treated for one to three recurrence locations, either successively or at the same time. At the time of last follow-up, only one patient had died following the metastatic evolution of their thymoma.

    With a median follow-up for the lesions of 20 months, local control was very good, since all lesions were reduced to a smaller, non-progressive mass or in complete metabolic response.

    No patient developed Grade 3 or higher acute or late toxicity.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Treatment of pleural recurrences of thymoma using SBRT with moderate doses allowed for good local control without increased toxicity, constituting a good alternative to surgery. This treatment could furthermore delay the use of chemotherapy.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.